xStep

xStep operates in neurotechnology and rehabilitation, with a non-invasive spinal cord neuromodulation device intended to support walking and balance. Its stated CDSCO certification for clinical and home use in India distinguishes its positioning around access across supervised care and home settings, although public information does not provide clinical outcome data, adoption figures, or details of the certification’s scope. The September 2026 collaboration with Trexo Robotics adds a complementary gait-training modality at xStep One, rather than positioning the company solely as a device maker. xStep says its therapy is powered by SpineX and manufactured by VIVATRONIX. The company is early-stage: it was founded in 2025, has disclosed two funding rounds, and most recently received seed backing from Titan Capital in September 2026. Its observable differentiation is therefore best described by the combination of spinal neuromodulation, stated Indian regulatory certification, a clinical-and-home-use focus, and the Trexo Robotics collaboration—not by an unverified claim of market leadership.

xStep’s disclosed timeline indicates an early-stage company moving from angel financing toward seed backing while developing a rehabilitation-focused offering. It was founded in 2025, and its first listed funding event was a $110,047 angel round on January 17, 2026, involving Namita Thapar, Vineeta Singh, and Kunal Bahl. On September 1, 2026, Titan Capital led a seed round; the round amount is not separately disclosed. The company reports $110,047 in total funding, so the available figures do not establish how much additional capital the seed round contributed. A second inflection point came in September 2026 with the announced Trexo Robotics collaboration, which brings a wearable robotic gait trainer to India for use alongside xStep therapy at xStep One. That partnership suggests an effort to broaden the rehabilitation offering beyond neuromodulation alone. xStep also states that its device is CDSCO-certified for clinical and home use in India. Further trajectory assessment depends on disclosed seed-round proceeds, deployment, and clinical outcomes.